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Cellular Stress Response 1 (CSR1) is a tumor suppres-
sor gene that is located at 8p21, a region that is fre-
quently deleted in prostate cancer as well as a variety
of human malignancies. Previous studies have indi-
cated that the expression of CSR1 induces cell death.
In this study, we found that CSR1 interacts with X-
linked Inhibitor of Apoptosis Protein (XIAP), using
yeast two-hybrid screening analyses. XIAP overex-
pression has been found in many human cancers,
and forced expression of XIAP blocks apoptosis. Both
in vitro and in vivo analyses indicated that the C-ter-
minus of CSR1 binds XIAP with high affinity. Through
a series of in vitro recombinant protein-binding anal-
yses, the XIAP-binding motif in CSR1 was determined
to include amino acids 513 to 572. Targeted knock-
down of XIAP enhanced CSR1-induced cell death,
while overexpression of XIAP antagonized CSR1 ac-
tivity. The binding of CSR1 with XIAP enhanced
caspase-9 and caspase-3 protease activities, and CSR1-
induced cell death was dramatically reduced on ex-
pression of a mutant CSR1 that does not bind XIAP.
However, a XIAP mutant that does not interact with
caspase-9 had no impact on CSR1-induced cell death.
These results suggest that cell death is induced when
CSR1 binds XIAP, preventing the interaction of XIAP
with caspases. Thus, this study may have elucidated a
novel mechanism by which tumor suppressors in-
duce cell death. (Am J Pathol 2012, 181:463–471; http://dx.
doi.org/10.1016/j.ajpath.2012.04.016)
Cellular Stress Response 1 (CSR1) is a stress response
gene located at 8p21, a region frequently deleted in
prostate cancer and several other human malignant tu-
mors.1–5 Homozygous deletion of CSR1 in prostate can-cer is rare.6 However, the promoter/exon 1 region of
CSR1 is frequently methylated in prostate cancer,6 and
this methylation is associated with prostate cancer re-
lapse. Forced expression of CSR1 in prostate cancer cell
lines such as PC3, LNCaP, and DU145 inhibits colony
formation, anchorage-independent growth, and invasion.
Similarly, following forced expression of CSR1 in PC3 and
DU145 xenograft mouse models, tumor volume and me-
tastasis are decreased, and the mice have higher sur-
vival rates. A recent study suggested that CSR1 induces
apoptosis and necrotic cell death by inhibiting polyade-
nylation of RNA through redistribution of a critical poly-
adenylation enzyme, CPSF3.7 However, cell death induc-
tion by CSR1 may not be explained solely by the
inhibition of CPSF3, as the extent of cell death induced by
CSR1 appeared to be more extensive than the reduction
of polyadenylated mRNA would warrant.
An X-linked inhibitor of apoptosis protein (XIAP) is a
crucial inhibitor of caspase-9, -3, and -7,8–10 and is ubiq-
uitously expressed in almost all adult and fetal tissues.
XIAP contains three baculovirus IAP repeat (BIR) do-
mains, a RING-finger domain conferring ubiquitin protein
ligase activity, and a ubiquitin-binding domain. XIAP
overexpression is found in many human malignant sam-
ples, and forced expression of XIAP blocks apoptosis.9 It
was shown that the mechanism of binding between the
BIR domains of XIAP and the IAP-binding motif in the
catalytic sites of caspases is two sited, facilitating potent
inhibition.8,10 The caspase inhibitory activity of XIAP is
regulated by several mitochondria molecules such as
HtrA2 and SMAC.11–13 These molecules contain the con-
served IAP-binding motif, and on release from the mito-
chondria, compete with caspases for XIAP binding, thus
relieving caspases from XIAP inhibition. However, little is
known about cytosolic or membranous inhibitors of XIAP.
In this study, we showed that CSR1, a scavenger mem-
branous protein, binds XIAP with high affinity on induction
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AJP August 2012, Vol. 181, No. 2of expression, and prevents XIAP-inhibition of caspase
activity, leading to apoptosis of CSR1-expressing cells.
Materials and Methods
Cell Lines and Culture
Prostate cancer cell lines, DU145 and PC3, and an im-
mortalized prostate epithelial cell line, RWPE-1, were pur-
chased from ATCC (Manassas, VA) in 2007. These cell
lines underwent one cycle of growth before being stored
in liquid nitrogen until needed. Cells were used for trans-
fections within 2 weeks of thawing. DU145 cells were cul-
tured in modified Eagle’s medium (Invitrogen, Carlsbad,
CA), and PC3 cells were cultured in F12K (Invitrogen) sup-
plemented with 10% fetal bovine serum (Cellgro, Manas-
sas, VA). RWPE-1 cells were cultured in keratinocyte serum-
free medium supplemented with 0.05 mg/mL bovine
pituitary extract and 5 ng/mL recombinant epidermal
growth factor (Invitrogen). All cell lines were maintained at
37°C and 5% CO2. Cell-permeable Caspase-9 Inhibitor II
was obtained from Calbiochem (Gibbstown, CA).
Plasmid Construction
For construction of pBD-CSR1c fusion proteins, a muta-
genic primer set (5=-TGTGGCCTATAATCATATGAATGTCA-
CCATCCTACGAGGTGCC-3= and 5=-TTCATTTCAAGCAA-
AGTCGACGCCTGGATCTGCTCTGCGCCCCTC-3=) was
designed to create two restriction sites, NdeI and SalI, in the
C-terminus (156 amino acids) of CSR1 so that the PCR
product could be ligated into a pGBK7T vector (Clontech,
Mountain View, CA). A PCR reaction was performed on
cDNA template isolated from a normal prostate sample
(Clontech), and the PCR conditions were as follows: 94°C
for 1 minute followed by 35 cycles of 94°C for 30 seconds
and 68°C for 3 minutes, and a final extension step for 3
minutes at 68°C. The PCR product was digested with NdeI
and SalI (New England Biolabs, Ipswich, MA), gel purified,
and ligated into a similarly digested pGBKT7 vector. The
fusion protein contained 156 amino acids from the CSR1
C-terminus. The construct was transformed into One Shot
competent cells (Invitrogen). Plasmid DNA was extracted
from selected transformed cells and digested with NdeI and
SalI to detect the presence of the insert. The coding frame
was confirmed by automated sequencing. Similar proce-
dures were performed for pBD-CSR1F and pAD-XIAP con-
struction, except using the following primer pairs: 5=-GATA-
TCATATGAAAGTGAGGTCGGCCGGC-3=/5=-GATATGT-
CGACGTCAGTAGAAGCTCT GGCTTCC-3= for pBD-CSR1F,
and 5=-GATATCATATGATGACTTTTAACAGTTTTGAA-3=/5=-
GATATCTCGAGTTTAAGACATAAAAATTTTTTGCTTG-3= for
pAD-XIAP. The construction of pGST-CSR1c and correspond-
ing mutants was described previously.7
The construction of pCDNA4-CSR1 is described else-
where.7 To construct pCDNA4-CSR1512–573, mutagenesis
PCR was performed. An upstream CSR1 fragment was
generated with the following primer set: 5=-GATATCTTAAG-
ACCATGGAAGTGAGGTCGGC-3=/5=-GTTCACCCTTAG-
GCCCCATAGGGCCCCTTTCTCCCACA-3=, and a down-
stream CSR1 fragment was generated with the followingprimer set: 5=-GATATGCGGCCGCCAGTAGAAG-
CTCTGGCTTCCTG-3=/5=-TGTGGGAGAAAGGGGCCC-
TATGGGGCCTAAGGGTGAAC-3=. These PCR products
were combined and reamplified by PCR using the follow-
ing primer set: 5=-GATATCTTAAGACCATGGAAGTGAG-
GTCGGC-3=/5=-GATATGCGGCCGCCAGTAGAAG-
CTCTGGCTTCCTG-3=. The PCR product was then di-
gested with AflII and XhoI, and ligated into a similarly
digested pCDNA4 vector.
Yeast Transformation and Library Screening
The yeast AH109 competent cell preparation was de-
scribed previously.14 In 0.6 mL of PEG/LiAc, 100 l of
freshly prepared AH109 competent cells were mixed with
plasmid pGBKT7-CSR1F (0.25 to 0.50 g) plus 0.5 g of
plasmid DNA from prostate cDNA library constructed in
pACT2, and the mixture was incubated at 30°C for 30
minutes. After this initial incubation with plasmid DNA, the
cell solution was combined with 70 L of dimethyl sulfox-
ide (DMSO; Sigma, St. Louis, MO) and incubated at 42°C
for 15 minutes. The cells were pelleted, resuspended in 0.5
mL of YPDA medium, and plated on minimum synthetic
dropout medium agar plates of increasing nutrient strin-
gency. The transformants were plated directly to low-, me-
dium-, or high-stringency medium plates, or the colonies
grown on the low (SD/-Leu/-Trp) and medium (SD/-Leu/-
Trp/-His) stringency plates were transferred to high-strin-
gency plates (SD/-Ade/-His/-Leu/-Trp and X--Gal). All col-
onies were subjected to the colony-lift filter -galactosidase
assay as described previously.15 pBD-53 and pAD-T anti-
gen were cotransformed into AH109 and used as a positive
control, and pBD-Lamin C was cotransformed with pAD-T
and used as a negative control. PCL1 transformed into
AH109 was used as a positive control for the galactosidase
assay.
Validation of Protein Interactions in AH109
Plasmid DNA from positive clones (blue colonies on the
high-stringency plate) was isolated from yeast and
transformed into Escherichia coli. E. coli were then se-
lected with ampicillin (100 g/mL) to obtain gene-ACT2
fusion proteins interacting with the bait-domain fusion
protein. To perform validation, cDNA of XIAP was li-
gated into pACT2 in frame. The pAD-XIAP DNA was
then cotransformed with pBD-CSR1c or pBD-CSR1F
into AH109 yeast cells and grown on an SD/-Ade/-His/-
Leu/-Trp high-stringency medium. -Galactosidase ac-
tivity was assayed by colony-lift filter in cells that grew
in this medium.
Glutathione S-Transferase Fusion Protein
Pull-Down
Cells were grown in 5 mL of Luria broth (ampicillin, 100
g/mL) overnight at 37°C. Cells were then diluted 20-fold
in Luria broth, and grown with shaking to OD 0.6 to 1.0.
Protein expression was induced by isopropyl -D-1-thio-
galactopyranoside (final concentration, 1 mmol/L) for 3
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PBS, and sonicated for 2 minutes. The proteins were
solubilized in 1% Triton X-100. The supernatant was col-
lected after centrifugation at 15,000  g for 5 minutes.
The GST and GST-CSR1c fusion proteins were purified
with a Glutathione Sepharose 4B column (Amersham
Pharmacia Biotech, Piscataway, NJ). The PC3 cell pro-
tein extract was preincubated with the column for 15
minutes at 4°C, and the flow-through was collected after
spinning at 3000  g for 1 minute. The flow-through cell
lysates were then incubated with GST fusion protein-
packed Glutathione Sepharose 4B at 4°C for 2 hours. The
column was spun at 3000  g at room temperature for 1
minute and washed twice with PBS. The protein was
eluted from the column with 40 l of SDS-PAGE gel
sample loading dye. SDS-PAGE and Western blot anal-
ysis were subsequently conducted.
Immunofluorescence Staining
RWPE1 cells were cultured on chamber slides for 24 h,
before slides were washed with PBS three times. The
cells were then fixed with 4% paraformaldehyde for 1
hour at room temperature. After washing the slides
twice with PBS, the cells were blocked with 10% don-
key serum with 0.4% Triton X-100. The cells were then
incubated with rabbit antisera against CSR1 and goat
antisera against XIAP (Santa Cruz Inc, Santa Cruz, CA)
at room temperature for 1 hour. The slides were
washed twice with PBS. Donkey anti-rabbit (fluoresce-
in-conjugated) and donkey anti-goat (rhodamine-con-
jugated) secondary antibodies were added and incu-
bated at room temperature for 1 hour. The slides were
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DAPI. After additional washes with PBS, slides were
mounted with Prolong Gold Antifade Reagent (Invitro-
gen). Immunofluorescence staining was examined un-
der a confocal microscope.
Fluorescence-Activated Cell Sorting Analysis of
Apoptotic Cells
Cells transfected with inducible CSR1 clones were plated
and treated with tetracycline (5 g/mL) as described
above. For UV treatment, RWPE1 cells were irradiated in
a Stratalinker UV box with a dosage of 16.7 mj/m2. Cell
death was analyzed 2 hours after UV treatment. These
cells were trypsinized and washed twice with cold PBS.
The cells were then resuspended in 100 l of annexin
binding buffer (Molecular Probes, Eugene, OR) and in-
cubated with 5 l of Alexa Fluor 488-conjugated annexin
V and 1 l of propidium iodide (PI; 100 g/mL) for 15
minutes in the dark at room temperature. The binding
assays were terminated by addition of 400 l of cold
annexin binding buffer. Fluorescence-activated cell sort-
ing (FACS) analysis was performed in a BD-LSR-II flow
cytometer (BD Sciences, San Jose, CA). The fluores-
cence stained cells were analyzed at 530 nm (FL1) and
575 nm (FL3). The negative control, cells incubated
without Alexa Fluor 488 or PI, was used to establish the
background setup in the acquisition. Cells stained with
annexin V only or PI only were used for calibration and
compensation before the acquisition. UV-treated cells
were used as positive controls for the apoptotic cells. For
each acquisition, 10,000 to 20,000 cells were sorted based
on the fluorescence color of the cells: only green (apoptotic
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Figure 1. The C-terminus of CSR1 binds XIAP. A: Constructs
of full-length CSR1 (pBD-CSR1F) and the CSR1 C-terminus
(pBD-CSR1c) bait domains for yeast two-hybrid analysis. Yeast
cotransformed with pBD-CSR1F and pBD-CSR1c with pAD-
XIAP were grown on an SD agar plate with high-stringency
nutrient selection (SD/-Leu/-Trp/-His/-Ade). B: Coimmunopre-
cipitation of XIAP or CSR1 using antibodies specific for CSR1 or
XIAP. Images represent the immunoprecipitates separated by
SDS-PAGE and incubated with the indicated antibodies. C:
Immunofluorescence staining of RWPE-1 cells with antibody
against XIAP (red) b and antibody against CSR1 (green). D:
GST-fusion proteins were used to map the XIAP-binding motif
of CSR1. Left: CSR1 deletion mutants with GST expression
vectors. Right: Representative binding assays performed with
GST or GST-CSR1 deletion mutants and XIAP from PC3 cell
(lanes 1 to 3) or HisTag-XIAP (lanes 4 to 12) lysate. Top panel:
Immunoblots with antibodies specific for XIAP. Bottompanel:
Coomassie staining of fusion proteins. E: Fusion proteins were
used to map the CSR1-binding motif of XIAP. Left: XIAP dele-
tion mutants with His-tag expression vectors. Right: Represen-
tative binding assays performed with HisTag-XIAP or deletion
mutants and GST-CSR1c. Top panel: Immunoblots with anti-
bodies specific for the CSR1 C-terminus. Bottom panel: Coo-
massie staining of proteins. Lane 1, HisTag-XIAP; lane 2,
HisTag-XIAPn; lane 3, HisTag-XIAPc; lane 4, HisTag-XIAPn1;    2   
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AJP August 2012, Vol. 181, No. 2cells), only red, both red and green (late apoptotic stage or
dead cells), or no color (live cells). WinMDI 2.9 software was
used to further analyze the data. For siRNA analysis, 125
pmol of siRNA specific for XIAP (5=-GAAUAAGAAGCAU-
CAUACUAUAACT-3=/5=-AGUUAUAGUAUGAUGCUUCU-
UAUUCUU-3=), or CSR1 (5=-UUGGAUUCCUUCCAGGCU-
GCRUCCUG-3=/5=-CAGGAGCAGCCUGGAAGGAAUC-
CAA-3=), or non-specific control (5=-UAAUGUAUUGGAA-
CGCAUAUU-3=/5=-UAUGCGUUCCAAUACAUUA-3=) was
transfected into PWC1 cells using the Lipofectamine 2000
Transfection Kit (Invitrogen,). Immunoblots and FACS anal-
yses were performed 24 hours after transfection.
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Figure 2. Knock-down of XIAP exacerbates cell death induced by CSR1.
pCDNA4-CSR1/pCDNA6) cells treated with or without tetracycline, and then
Inhibitor II (IC, 1 g/mL). Cells were harvested for analyses 48 hours after tra
transfected with a scrambled siRNA (Scr), XIAP-siRNA (siXIAP), or Caspase-9
each condition were averaged in the analyses. *P  0.001. C: Representativ
Table 1. Impact of BCL2 Expression on CSR1-Induced Cell Deat
Cell Induction Vector
WCRS1 Tet pCMVscript
Tet pCMVscript
Tet pCMV-Bcl2
Tet pCMV-Bcl2
WCRS1–2 Tet pCMVscript
Tet pCMVscript
Tet pCMV-Bcl2
Tet pCMV-Bcl2pCMV, cytomegalovirus plasmid; Tet, tetracycline; WCSR1, PC3 cells transfoCaspase-9 and Caspase-3 Activity Assays
To investigate the protease activity of caspase-9, the
Caspase-9/Mch6 Colorimetric Assay Kit from MBL Inter-
national (Woburn, MA) was used. Briefly, WCSR1 cells
were treated with or without tetracycline (5 g/mL) for 3
days, and then lysed with RIPA buffer. Caspase-9 was
then immunoprecipitated with mouse monoclonal anti-
body specific for caspase-9. The caspase-9/Mch6 color-
imetric assay was performed by adding LEHD-pNA sub-
strates to a final concentration of 200 mol/L in a reaction
volume of 50 l. Protease assays were carried out at
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protease activity was quantified in a spectrophotometer
at 400 nmol/L. Immunoprecipitates without primary anti-
body were used as negative controls. For caspase-3
activity assays, the cell lysate of each sample was trans-
ferred to a 96-well black plate, and 5 l of caspase-3
substrate (DEVD-AFC) and 50 l of reaction buffer were
added to each reaction. After incubation at 37°C for 1 h,
caspase-3 activity was quantified in a fluorometer at 400
nm/505 nm. Experiments with caspase-3 inhibitor or with-
out caspase-3 substrate were used as controls.
Results
The mechanism of CSR1 tumor suppressor activity re-
mains to be elucidated. To investigate the CSR1 signal-
ing pathway that leads to suppression of tumor growth,
we performed a yeast two-hybrid screen on a prostate
pACT2-cDNA library using pBD-CSR1F as a probe.
Forty-five colonies that grew on the SD/-Ade/-His/-Leu/-Trp
nutrient-selective medium plate and were positive for X--
Gal hydrolysis were identified. After eliminating redundant
clones, 26 unique positive clones were identified. One of
these clones was identified as XIAP. To validate the inter-
action of CSR1 and XIAP, XIAP cDNA was ligated into the
pACT2 vector in frame with the activation domain of GAL4
to generate pAD-XIAP. This construct was then cotrans-
fected with pBD-CSR1F into yeast AH109 cells and grown
in SD/-Ade/-His/-Leu/-Trp, and tested for galactosidase ac-
tivity. As shown in Figure 1A, yeast harboring either the
full-length CSR1 or the C-terminus of CSR1 grew on the
stringent nutrient selective medium plate and had galacto-
sidase activity, whereas yeast harboring laminin C and T-
antigen (negative control) failed to grow under these con-
ditions.
To investigate whether the binding of CSR1 and XIAP
occurs in vivo, coimmunoprecipitation of CSR1 and XIAP
was performed on protein extract from RWPE1 cells, an
immortalized prostate epithelial cell line. CSR1 and XIAP
were coimmunoprecipitated when either anti-CSR1 or anti-
XIAP antibodies were used (Figure 1B). Immunofluores-
cence staining of CSR1 and XIAP suggests that CSR1 and
XIAP are co-localized in the cytoplasm and plasma mem-
brane (Figure 1C). To examine whether CSR1 binds XIAP in
vitro, fragments of CSR1 were ligated into pGEX5x in frame
to create GST-CSR1 fusion proteins. GST-CSR1c (C-termi-
nus of CSR1) bound XIAP, whereas the N-terminus and the
mid-segment of CSR1 did not (Figure 1D). Subsequently, a
series of CSR1 C-terminus deletion mutants were made.
The binding analyses of XIAP with these mutants revealed
that the binding motif is located at amino acids 513 to 572,
as all mutants containing this sequence bound XIAP,
whereas mutants without this sequence failed to bind XIAP
(Figure 1, D and E).
XIAP is a critical inhibitor of apoptosis, so we next
investigated the role of XIAP in CSR1-induced cell death.
As shown in Figure 2, A and B, induction of CSR1 ex-
pression in PC3 cells mediated a fourfold increase in cell
death. However, knock-down of XIAP expression en-
hanced the effect of CSR1 by increasing cell death by an
additional 58% (from 43% to 68%, P  0.001, Figure 2, Band C). Interestingly, expressing BclII using pCMV-BclII
did not have a significant impact on CSR1-induced cell
death (Table 1), suggesting that CSR1 is a downstream
signaling molecule in cell death induction. Treatment of
cells with membrane-permeable caspase-9 Inhibitor II, a
16–amino acid peptide that inhibits caspase-9, -4, and
-5, reversed cell death induced by CSR1 and siXIAP
(Figure 2), suggesting that the CSR1-induced cell death
requires caspase activity. Because binding of XIAP with
caspase-3, -7, and -9 inhibits the protease activity of
these caspases, we then investigated the effect of CSR1
expression on the activity of caspase-9, the initiator of the
caspase cascade, in PC3 cells. Induction of CSR1 ex-
A
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Figure 3. CSR1 activates the protease activity of caspase-9 and -3. A: Im-
munoblot analysis of CSR1, XIAP and -actin. WCSR1 (PC3 transformed with
pCDNA4-CSR1/pCDNA6) cells were transfected with siXIAP or scramble
control (Scr), and treated with or without tetracycline for 48 hours. The cell
lysates were separated by SDS-PAGE and then immunoblotted with the indi-
cated antibodies. Similar tetracycline treatment and assays were performed with
CSR1-5 cells (pCDNA4-CSR1513–572/pCDNA6 transformed PC3 cells). B: Acti-
vation of caspase-9 by CSR1 is dependent on XIAP. WCSR1 or CSR1-5 cells
were transfected with siXIAP or Scr and treated with tetracycline to express
wild-type or mutant CSR1, respectively, and cell lysates were incubated with
caspase-9 substrate (LEHD-pNA). The protease activity of caspase-9 was then
quantified in a spectrophotometer. Triplicate experiments of each treatment
were analyzed. Reactions without caspase-9 substrate were used as negative
controls. *P 0.01; **P 0.001. C: Activation of caspase-3 by CSR1 is dependent
on XIAP. WCSR1 or CSR1-5 cells were transfected with siXIAP or Scr, and
treated with tetracycline to express wild-type or mutant CSR1, respectively, and
cell lysates were incubated with caspase-3 substrate (DEVD-AFC). The protease
activity of caspase-3 was then quantified in a spectrofluorometer. Triplicate
experiments of each treatment were analyzed. Reactions without caspase-3
substrate were used as negative controls. The specificity of the assay was
evaluated using caspase-3 inhibitor. *P  0.01; **P  0.001.
*P  0.0
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AJP August 2012, Vol. 181, No. 2pression resulted in a 46% increase in caspase-9 activity
(P  0.004). This increase in protease activity was dra-
matically enhanced (2.8-fold, P  0.001) when XIAP was
down-regulated by siRNA specific for XIAP (Figure 3, A
and B). Similarly, the activity of caspase-3 was increased
by 48% (P  0.003) on induction of CSR1. The induction
of protease activity was reversed by treatment with a
caspase-3–specific inhibitor (Figure 3C), indicating the
specificity of the assay. These results suggest that the pres-
ence of XIAP prevents the activity of CSR1 in inducing cell
death. The binding of CSR1 and XIAP serves to relieve XIAP
inhibition of caspase-9 and -3 protease activity.
To investigate the role of the CSR1/XIAP interaction in
CSR1-induced cell death, a mutant CSR1 that lacks the
motif for XIAP binding (CSR1513–572) was created. The
mutant CSR1 was then ligated into pCDNA4 to create
pCNDA4-CSR1. pCDNA4-CSR1/pCDNA6 were then
transfected into PC3 cells to generate a cell line that
expresses a mutant CSR1 that does not interact with XIAP
on tetracycline treatment. Cell death observed after the
induction of mutant CSR1513–572 expression in PC3 cells
was greatly reduced compared with cell death mediated
by wild-type CSR1 (P 0.001) (Figure 4, A–C). This result
suggests that the XIAP/CSR1 interaction plays an impor-
tant role in mediating cell death induced by CSR1, prob-
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Figure 4. Loss of the XIAP-binding motif in CSR1 abrogates CSR1-induce
transformed with pCDNA4-CSR1/pCDNA6), WCSR1–4 (PC3 transformed with
pCDNA6), and CSR1–7 (PC3 transformed with pCDNA4-CSR1513–572/pCDN
of cell death in A. Triplicate experiments of each treatment were analyzed.
iodide staining of cells in A.ably through inactivation of inhibition activity of XIAP.Indeed, in contrast to wild-type CSR1, induction of
CSR1513–572 expression did not increase the protease
activity of caspase-9 or -3 (Figure 3, B and C). To rule out
the possibility that functions of XIAP other than
caspase inhibition were involved in the CSR1-mediated
cell death, we generated a point mutation in XIAP
(XIAPe314s) that prevents XIAP binding to caspases,
and overexpressed it in PC3 cells. If CSR1-induced cell
death is mediated by neutralizing the non–caspase
inhibition function of XIAP, overexpression of mutant
XIAPe314s may antagonize CSR1-induced cell death.
However, as shown in Figure 5, our study indicates that
overexpression of XIAPe314s had minimal impact on
CSR1-induced cell death, whereas the wild-type XIAP
reduced CSR1-induced cell death by half (P  0.001),
suggesting that de-inhibition of caspases plays a ma-
jor role in CSR1-induced cell death.
CSR1 is one of the cell stress response proteins that
can be induced by UV, X-ray irradiation, or reactive ox-
ygen species.16 To investigate the physiological rele-
vance of CSR1-induced cell death, we investigated
RWPE-1 and PC3 cells, in which expression of CSR1 is
inducible by UV irradiation (Figure 6A). UV treatment of
RWPE1 cells eliminated 98% of colony-forming cells,
whereas treatment with CSR1-specific siRNA increased
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AJP August 2012, Vol. 181, No. 2after UV irradiation, CSR1 expression was significantly
increased in both PC3 and RWPE-1 cells, and cell death
was increased by an average of 12-fold (PC3 cells) and
fourfold (RWPE-1 cells) (P 0.001). However, RWPE-1 or
PC3 cells in which CSR1 was knocked down experienced
significantly less cell death compared with the scramble
controls (P  0.001). These results suggest that CSR1
plays a critical role in UV-induced apoptosis.
Discussion
CSR1 is a membranous scavenger protein known for its
role in inducing cell death.7 XIAP is involved in multiple
cell functions, including ubiquitin ligation and inhibition of
caspases.17,18 XIAP is the only human protein that inhib-
its caspase activities at both the initiator and effector
levels. The present study indicates that CSR1 interacts
with and inhibits XIAP both in vivo and in vitro. Several
lines of evidence support the conclusion that CSR1 binds
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Figure 5. Overexpression of XIAP antagonizes CSR1-induced cell dea
transformed with pCDNA4-CSR1/pCDNA6) cells transfected with pCMVscr
The cell lysates were then separated by SDS-PAGE and identified with the
experiments of each treatment were analyzed. *P  0.001. C: Representa
listed in A.with XIAP. First, both full-length CSR1 and the C-terminusof CSR1 bound XIAP in the yeast two-hybrid system and
in cell-free in vitro binding assays. The binding of the
recombinant CSR1 C-terminus and XIAP in the cell-free
system suggests that no bridge protein is involved in the
CSR1/XIAP interaction. Second, both CSR1 and XIAP
were readily coimmunoprecipitated from prostate epithe-
lial cells by antibodies against either XIAP or CSR1, sug-
gesting the CSR1/XIAP interaction occurs intracellularly.
Third, CSR1 and XIAP colocalized in the cytoplasm and
at the plasma membrane of the immortalized prostate
epithelial cells.
A previous study suggests that CSR1 induces cell death
through redistribution of CPSF3 and inactivation of its poly-
adenylation activity.7 This study indicates that CSR1 inhibits
XIAP activity, which would lead to higher levels of
caspase-9 and -3 activity on CSR1 expression. Knock-
down of XIAP enhanced CSR1-induced cell death. Cells
expressing mutant CSR1 that does not bind XIAP expe-
rienced significantly less cell death but displayed change
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This study also confirms the previous finding that CSR1
expression is induced by cellular stress, such as UV light
treatment. Interestingly, CSR1 appears to be a key signal-
ing molecule for UV light–induced cell death, as elimination
of CSR1expression by siRNA dramatically attenuated the
UV-induced cell death responses. Thus, CSR1-CPSF3 and
CSR1-XIAP signaling are critical mechanisms for cellular
response to stress.
XIAP belongs to a family of proteins homologous to
baculovirus IAP, and is involved in suppression of cell
death.19–21 Since its discovery, XIAP has been found to
participate in a variety of cellular processes, including
ubiquitin ligation, apoptosis, motility, and gene expres-
sion regulation.9,12,22–25 The discovery of a XIAP/CSR1
interaction adds a novel function for XIAP as a down-
stream signaling molecule for a tumor suppressor. The
involvement of XIAP in CSR1-induced cell death appears
to be critical because a CSR1 mutant lacking the XIAP-
binding motif is unable to induce cell death. The motifs for
XIAP and CPSF3 do not overlap but are only 30 amino
acids apart. The dependency of CSR1 on XIAP to induce
cell death raises the possibility that the CSR1-CPSF3-
XIAP complex needs to be intact to be functional. It is not
clear whether CPSF3 and XIAP interact, however. Alter-
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Figure 6. Knock-down of CSR1 partially blocks UV-induced apoptosis. A
siRNA specific for CSR1 (siCSR1) or scramble control (Scr), and treated wit
and identified with the indicated antibodies. B: Colony formation analy
irradiation and siCSR1 or Scr. Colony formations were tabulated 10 days
Triplicate experiments of each treatment were analyzed. *P  0.001. D: Re
of cells in A.natively, deletion of the XIAP-binding motif of CSR1 mayproduce an allosteric effect that adversely affects the
function of CSR1. The CSR1 binding domain in XIAP
appears in the sequence containing BIR1 which is a
different location from the binding sites for caspase-3
and -9. This suggests that CSR1 does not directly com-
pete with caspase-3 or -9 for XIAP binding. Likely, the
binding of CSR1 and XIAP generates an allosteric effect
or a physical hindrance that interferes with the interaction
between XIAP and caspases. A physical structure anal-
ysis of CSR1-XIAP complex may shed light on the mech-
anism of CSR1-mediated XIAP inhibition. Based on the
current analysis, CSR1 appears to hijack XIAP from per-
forming its caspase inhibition function.
CSR1 remains an enigmatic protein, the physiological
function of which is not fully understood. Low levels of
CSR1 expression are found in almost all normal tissues.6
The response of CSR1 to cell stress and its ability to
induce cell death might suggest that CSR1 has a function
similar to that of a typical tumor suppressor gene such as
p53. Even though CSR1 is located in a chromosomal
region known to be frequently deleted in a variety of
cancers, there is no report suggesting that CSR1 is mu-
tated in cancers. The high frequency of CSR1 methylation
observed in prostate cancer samples suggests that epi-
genetic alteration is the main mechanism for inactivation
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AJP August 2012, Vol. 181, No. 2in CSR1 promoter regions correlates with poor clinical
prognosis for patients with prostate cancer, it is possible
that restoring the expression of CSR1 in cancer cells
could reduce tumor invasiveness, tumor growth, and pa-
tient mortality associated with this disease.
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